Capsovision (CV) closed at $6.03 on November 13, 2026, down 3.8% from the previous close, on volume of 163,728 shares (30-day average 116,215).
Data as of November 13, 2026.
CapsoVision Earnings Call Highlights AI and Growth Progress
TipRanks (Fri, 13-Nov 7:05 PM ET)
CapsoVision, Inc. GAAP EPS of -$0.15 misses by $0.01, revenue of $3.6M misses by $0.16M
Seeking Alpha News (Fri, 13-Nov 9:51 AM ET)
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks (Fri, 13-Nov 9:01 AM ET)
CapsoVision Reports Third Quarter 2026 Financial Results
Globe Newswire (Thu, 12-Nov 4:05 PM ET)
CapsoVision to Release Third Quarter 2026 Financial Results on November 12, 2026
Globe Newswire (Thu, 29-Oct 4:05 PM ET)
CapsoVision to Present at the 20th Annual LD Micro Main Event
Globe Newswire (Tue, 13-Oct 4:05 PM ET)
CapsoVision Announces FDA Clearance of AI Highlights for CapsoCam Plus
Globe Newswire (Mon, 28-Sep 9:00 AM ET)
CapsoVision to Participate in Upcoming Investor Conferences
Globe Newswire (Thu, 3-Sep 4:05 PM ET)
Market Chameleon (Mon, 23-Mar 7:43 AM ET)
CapsoVision Inc is a commercial-stage medical technology enterprise that innovates, manufactures, and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal (GI) system. The company's core technology platform is an orally ingestible capsule including multiple cameras facilitating 360-degree imaging, light-emitting diodes for measurement, onboard memory storage, and battery life permitting recording and onboard storage of video images. CapsoVision's products consist of the on-market CapsoCam Plus, directed at the small intestines, and the in-development CapsoColon 3D, directed at the large intestines. Geographically, the company generates the majority of its revenue from the United States.
Capsovision trades on the NASDAQ stock market under the symbol CV.
As of November 13, 2026, CV stock price declined to $6.03 with 163,728 million shares trading.
CV has a beta of -1.82, meaning it tends to be less sensitive to market movements. CV has a correlation of 0.05 to the broad based SPY ETF.
CV has a market cap of $320.86 million. This is considered a Small Cap stock.
Last quarter Capsovision reported $4 million in Revenue and -$.15 earnings per share. This fell short of revenue expectation by $-198,800 and met earnings estimates .
The top ETF exchange traded funds that CV belongs to (by Net Assets): VTI, IWM, VXF, IWO, VTWO.
CV has underperformed the market in the last year with a price return of +6.3% while the SPY ETF gained +13.4%. CV has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -11.2% and -11.7%, respectively, while the SPY returned -2.8% and -0.2%, respectively.
CV support price is $6.02 and resistance is $6.52 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CV shares will trade within this expected range on the day.